论文部分内容阅读
目的：探讨阿卡波糖用于治疗精神分裂症患者在奥氮平治疗后出现的体质量增加及代谢改变的有效性。方法接受奥氮平单药治疗、并出现有临床意义体重显著增加（≥7%）的精神分裂症患者随机分为两组，分别加用阿卡波糖300mg/d（阿卡波糖组，n=26）、二甲双胍750mg/d（对照组，n=26）辅助治疗，于治疗前及治疗后4、8周末测定体质量指数（BMI）、空腹血糖（FPG）、甘油三酯（TG）、总胆固醇（TC）及稳态模型评估的胰岛素抵抗指数（HOMA-IR）。结果①阿卡波糖组8w时BMI较治疗前显著下降（=2.309，0.05），对照组8w时FPG显著下降（=2.280，<0.05）；阿卡波糖组及对照组4w（分别t=2.499、2.431，均<0.05）、8w时TG（分别=2.881、2.803，均<0.01）均较治疗前显著下降；阿卡波糖组8w时TC显著下降（t=2.685，0.05）；两组治疗4、8 w时的HOMA-IR均较治疗前显著下降（越2.177-2.500，均0.05）。结论阿卡波糖可降低奥氮平所致体质重增加，疗效与二甲双胍相近、但起效慢；对代谢紊乱也有改善作。“,”Objective This study was to assess the efficacy of acarbose on relief of olanzapine-induced weight gain and metabolic dysfunction. Methods In the 8 week controlled study,schizophrenic patients suffering from olanzapine-induced weight gain were randomly divided into two treatment groups,one with acarbose (300mg/d, acarbose group,n=26 ),one with metformin (750 mg/d, control group,n=26 ). The body mass index (BMI), fasting plasma glucose (FPG),TG, TC and homeostasis model assessment of insulin resistance index (HOMA-IR) were measured from baseline to week 4,8 after treatment.Results There was a significant decrease in BMI from baseline to week 8 in acarbose group (t=2.309, <0.05)and in control group at 4, 8 weekend (t=2.378,2.508;boyh 0.05).After 8 week intervent-ion , FPG was significantly decreased in control group(t=2.280,0.05).TG was lower at 4 weekend (t=2.499,2.431;both <0.05)or 8 weekend (t=2.881,2.803;both P<0.01)in either acarbose group or control group.TC was decreased in acarbose group at end of 8 week (t=2.685 ,0.05). The HOMA-IR were significantly lower from baseline to week 4.8 in both two group (t=2.177-2.500 ,all 0.05).Conclusion Acarbose addition therapy has a considerable but later effectiveness in attenuating olanzapine-induced weight gain compared to metformin, and has a benefit on relief of metabolic dyfunction in schizophrenia patients.